Contents
- 1 Summary
- 2 Legal status
- 3 FAQ
- 3.1 1. What is 5-methylethylone?
- 3.2 2. How does 5-methylethylone relate to other designer drugs?
- 3.3 3. Is 5-methylethylone approved for human consumption by the FDA in the United States?
- 3.4 4. What is the legal status of 5-methylethylone in the United States?
- 3.5 5. Are there known risks associated with 5-methylethylone use?
- 3.6 6. Is 5-methylethylone widely available as a recreational drug?
- 3.7 7. Is 5-methylethylone classified as a controlled substance in the United States?
- 4 References
Summary
5-Methylethylone, also known as 5-methyl-βk-MDEA or 5ME, falls within the amphetamine, phenethylamine, and cathinone chemical classes, making it a versatile compound with empathogenic, stimulant, and psychedelic properties. This substance shares structural similarities with ethylone, another designer drug. However, limited information is available regarding the pharmacological characteristics, metabolism, and potential toxicity of 5-methylethylone despite its presence in the designer drug market.
| Identifiers | |
|---|---|
| CAS Number | 1364933-82-3 |
| 3D model (JSmol) | Interactive image |
| ChemSpider | 29763704 |
| PubChemCID | 112500536 |
| UNII | 3U77H8TN7N |
| SMILES | |
| Properties | |
|---|---|
| Chemical formula | C13H17NO3 |
| Molar mass | 235.283 g·mol−1 |
Legal status
United States: 5-Methylethylone is not classified under any specific schedule in the United States. However, it is important to note that the Food and Drug Administration (FDA) has not granted approval for its consumption by humans. Additionally, the state of Vermont has categorized it as a regulated drug.
FAQ
1. What is 5-methylethylone?
5-Methylethylone, also known as 5-methyl-βk-MDEA or 5ME, is a drug that belongs to the amphetamine, phenethylamine, and cathinone chemical classes. It is recognized for its empathogenic, stimulant, and psychedelic properties.
2. How does 5-methylethylone relate to other designer drugs?
5-Methylethylone shares structural similarities with ethylone, another designer drug. These compounds fall into the same chemical classes and are often considered novel psychoactive substances.
3. Is 5-methylethylone approved for human consumption by the FDA in the United States?
No, 5-methylethylone is not currently approved for human consumption by the Food and Drug Administration (FDA) in the United States. It is essential to exercise caution when considering its use.
4. What is the legal status of 5-methylethylone in the United States?
5-Methylethylone is not scheduled under specific drug categories in the United States. However, knowing that the FDA has not approved its use in humans is essential. Additionally, the state of Vermont has categorized it as a regulated drug.
5. Are there known risks associated with 5-methylethylone use?
Due to limited available data, the pharmacological properties, metabolism, and potential toxicity of 5-methylethylone are not well understood. As with any psychoactive substance, there may be associated risks, including physical and psychological effects. It is advisable to prioritize safety and informed decision-making.
6. Is 5-methylethylone widely available as a recreational drug?
The availability of 5-methylethylone can vary, and it is often sold as a designer drug. Its prevalence and accessibility may differ by region and over time.
7. Is 5-methylethylone classified as a controlled substance in the United States?
Currently, 5-methylethylone is not classified under any specific schedule as a controlled substance in the United States. However, its status may be subject to change based on regulatory decisions. Always stay informed about local and federal regulations.
References
- “3,4-Methylenedioxy-5-methylethcathinone (hydrochloride)”. This compound reference is provided by Cayman Chemical, a source for scientific and research materials.
- Assi S, Gulyamova N, Kneller P, Osselton D (May 2017). “The effects and toxicity of cathinones from the users’ perspectives: A qualitative study”. This study, published in Human Psychopharmacology, explores the effects and toxicity of cathinones, including user perspectives. [DOI: 10.1002/hup.2610]
- Schifano F, Napoletano F, Arillotta D, Zangani C, Gilgar L, Guirguis A, et al. (March 2020). “The clinical challenges of synthetic cathinones”. Published in the British Journal of Clinical Pharmacology, this research addresses the clinical challenges associated with synthetic cathinones. [DOI: 10.1111/bcp.14132]
- Regulated Drugs Rule, Vermont Health Regulations: This reference pertains to the Regulated Drugs Rule within Vermont Health Regulations, which may include information about controlled substances and their legal status in the state of Vermont.